目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 STUDY SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 INSIGHTS OF PRIMARY EXPERTS
2.2.2 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 BIOMARKERS MARKET OVERVIEW
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING
4.3 BIOMARKERS MARKET SHARE, BY END USER, 2024
4.4 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing use of biomarkers in drug discovery & development
5.2.1.2 Growing importance of companion diagnostics
5.2.1.3 Rising prevalence of cancer
5.2.1.4 Development of biomarkers for rare diseases
5.2.1.5 Increasing funds and grants for biomarker research
5.2.1.6 Advancement in omics technologies
5.2.2 RESTRAINTS
5.2.2.1 High capital investments and extensive timelines for biomarker development
5.2.2.2 Disease complexity and heterogeneity
5.2.3 OPPORTUNITIES
5.2.3.1 Growing preference for personalized medicine and precision oncology
5.2.3.2 Enhanced collaboration among healthcare providers and key industry players
5.2.3.3 High growth potential of emerging economies
5.2.4 CHALLENGES
5.2.4.1 Issues associated with quantification & validation of biomarkers
5.2.4.2 Complexities associated with data set integration
5.2.4.3 Technical issues related to sample collection and storage
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 REGULATORY ANALYSIS
5.4.1 REGULATORY SCENARIO
5.4.1.1 US
5.4.1.2 Europe
5.4.1.3 Asia Pacific
5.4.1.4 Rest of the World
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGICAL ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Immunoassays
5.6.1.1.1 Immunohistochemistry (IHC)
5.6.1.1.2 ELISA
5.6.1.2 Next-generation Sequencing (NGS)
5.6.1.3 Polymerase chain reaction (PCR)
5.6.1.4 In situ hybridization
5.6.1.5 Microarrays
5.6.1.6 Mass Spectrometry
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Liquid biopsy
5.6.2.2 CRISPR
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Artificial intelligence (AI) and machine learning (ML)
5.6.3.2 Sensors (wearable devices)
5.7 PRICING ANALYSIS
5.7.1 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024
5.7.2 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024
5.8 PATENT ANALYSIS
5.8.1 METHODOLOGY
5.8.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025
5.9 ECOSYSTEM ANALYSIS
5.10 KEY CONFERENCES & EVENTS, 2025-2026
5.11 PORTER'S FIVE FORCES ANALYSIS
5.11.1 INTENSITY OF COMPETITIVE RIVALRY
5.11.2 BARGAINING POWER OF SUPPLIERS
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 THREAT OF SUBSTITUTES
5.11.5 THREAT OF NEW ENTRANTS
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BIOMARKERS MARKET: BUYING CRITERIA
5.13 INVESTMENT & FUNDING SCENARIO
5.14 TRADE DATA ANALYSIS
5.14.1 IMPORT SCENARIO: HS CODE 382200, 2020-2024
5.14.2 EXPORT SCENARIO: HS CODE 382200, 2020-2024
5.15 IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET
5.15.1 INTRODUCTION
5.15.2 USE CASES
5.15.3 FUTURE OF AI IN BIOMARKER ECOSYSTEM
5.16 IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET
5.16.1 KEY TARIFF RATES
5.16.2 PRICE IMPACT ANALYSIS
5.16.3 IMPACT ON COUNTRIES/REGIONS
5.16.3.1 US
5.16.3.2 Europe
5.16.3.3 Asia Pacific
5.16.4 IMPACT ON END-USE INDUSTRIES
5.16.4.1 Pharmaceutical & biotech companies
5.16.4.2 Hospitals & diagnostic laboratories
5.16.4.3 Contract research organizations

6 BIOMARKERS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 ASSAY KITS
6.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
6.2.2 REAGENTS & CHEMICALS
6.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand
6.2.3 OTHER CONSUMABLES
6.3 SERVICES
6.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
6.4 SOFTWARE
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

7 BIOMARKERS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 SAFETY BIOMARKERS
7.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH
7.3 EFFICACY BIOMARKERS
7.3.1 PREDICTIVE BIOMARKERS
7.3.1.1 Rising applications of biomarkers in personalized medicine to drive market
7.3.2 SURROGATE BIOMARKERS
7.3.2.1 Ability to serve as reliable indicator in place of clinical endpoints to support market growth
7.3.3 PHARMACODYNAMIC BIOMARKERS
7.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
7.3.4 PROGNOSTIC BIOMARKERS
7.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers
7.4 VALIDATION BIOMARKERS
7.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

8 BIOMARKERS MARKET, BY RESEARCH AREA
8.1 INTRODUCTION
8.2 GENOMICS
8.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
8.3 PROTEOMICS
8.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
8.4 METABOLOMICS
8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
8.5 OTHER RESEARCH AREAS

9 BIOMARKERS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 IMMUNOASSAYS
9.2.1 ELISA
9.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth
9.2.2 PROTEIN MICROARRAYS
9.2.2.1 Quick and cost-effective nature of technology to support growth
9.2.3 WESTERN BLOT
9.2.3.1 Increasing investments in proteomics research to drive market
9.3 NEXT-GENERATION SEQUENCING (NGS)
9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
9.4 POLYMERASE CHAIN REACTION (PCR)
9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
9.5 MASS SPECTROMETRY
9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH
9.6 CHROMATOGRAPHY
9.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
9.7 OTHER TECHNOLOGIES

10 BIOMARKERS MARKET, BY DISEASE INDICATION
10.1 INTRODUCTION
10.2 CANCER
10.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
10.3 INFECTIOUS DISEASES
10.3.1 INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND
10.4 IMMUNOLOGICAL DISORDERS
10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET
10.5 NEUROLOGICAL DISORDERS
10.5.1 WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH
10.6 CARDIOVASCULAR DISORDERS
10.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
10.7 OTHER DISEASE INDICATIONS

11 BIOMARKERS MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL DIAGNOSTICS
11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
11.3 DRUG DISCOVERY & DEVELOPMENT
11.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
11.4 PERSONALIZED MEDICINE
11.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
11.5 CLINICAL RESEARCH
11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
11.6 OTHER APPLICATIONS

12 BIOMARKERS MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES
12.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
12.3 HOSPITALS & DIAGNOSTIC LABORATORIES
12.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
12.4 ACADEMIC & RESEARCH INSTITUTES
12.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
12.5 OTHER END USERS

13 BIOMARKERS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
13.2.2 US
13.2.2.1 Rising focus on biopharma research to support growth
13.2.3 CANADA
13.2.3.1 Increasing incidence of cancer to drive biomarkers market growth
13.3 EUROPE
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2 GERMANY
13.3.2.1 Growth in biopharmaceutical R&D activities to propel growth
13.3.3 UK
13.3.3.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
13.3.4 FRANCE
13.3.4.1 Increasing government investment for proteomics & genomics research to drive growth
13.3.5 ITALY
13.3.5.1 Increasing developments in life science research to fuel growth
13.3.6 SPAIN
13.3.6.1 R&D initiatives for personalized medicine to support market growth
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2 CHINA
13.4.2.1 Rising incidence of CVD to propel market
13.4.3 JAPAN
13.4.3.1 Strong regulatory guidelines for drug discovery & development to support market growth
13.4.4 INDIA
13.4.4.1 Favorable scenario for FDI and increasing number of clinical trials to propel market
13.4.5 SOUTH KOREA
13.4.5.1 Increasing innovations in NGS technologies to support market growth
13.4.6 AUSTRALIA
13.4.6.1 Increasing demand for diagnostic solutions to propel market
13.4.7 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2 BRAZIL
13.5.2.1 Increased government investments in pharmaceutical R&D to drive market
13.5.3 MEXICO
13.5.3.1 Rising demand for chronic disease treatment to support market growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
13.6.2 GCC COUNTRIES
13.6.3 SAUDI ARABIA
13.6.3.1 Growing healthcare expenditure to boost market growth
13.6.4 UAE
13.6.4.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth
13.6.5 REST OF GCC COUNTRIES
13.6.5.1 Other GCC countries include Bahrain, Kuwait, Oman, and Qatar.
13.6.6 REST OF MIDDLE EAST
13.6.6.1 The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq.
13.7 AFRICA
13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
14.3 REVENUE ANALYSIS, 2022-2024
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Offering footprint
14.5.5.4 Technology footprint
14.5.5.5 Application footprint
14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of key startups/SMEs
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 VALUATION OF KEY PLAYERS
14.7.2 FINANCIAL METRICS OF KEY PLAYERS
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
14.8.1 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES & APPROVALS
14.9.2 DEALS
14.9.3 EXPANSIONS

15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 THERMO FISHER SCIENTIFIC INC.
15.1.1.1 Business overview
15.1.1.2 Products & services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches & approvals
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 MnM view
15.1.1.4.1 Right to win
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses & competitive threats
15.1.2 MERCK KGAA
15.1.2.1 Business overview
15.1.2.2 Products & services offered
15.1.2.3 Recent developments
15.1.2.3.1 Deals
15.1.2.3.2 Expansions
15.1.2.4 MnM view
15.1.2.4.1 Right to win
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 F. HOFFMANN-LA ROCHE LTD.
15.1.3.1 Business overview
15.1.3.2 Products & services offered
15.1.3.3 Recent developments
15.1.3.3.1 Product launches & approvals
15.1.3.3.2 Deals
15.1.4 QIAGEN
15.1.4.1 Business overview
15.1.4.2 Products & services offered
15.1.4.3 Recent developments
15.1.4.3.1 Product launches & approvals
15.1.4.3.2 Deals
15.1.4.3.3 Expansions
15.1.5 ABBOTT
15.1.5.1 Business overview
15.1.5.2 Products & services offered
15.1.5.3 Recent developments
15.1.5.3.1 Product launches & approvals
15.1.5.3.2 Deals
15.1.6 AGILENT TECHNOLOGIES, INC.
15.1.6.1 Business overview
15.1.6.2 Products & services offered
15.1.6.3 Recent developments
15.1.6.3.1 Product launches & approvals
15.1.6.3.2 Deals
15.1.7 REVVITY INC.
15.1.7.1 Business overview
15.1.7.2 Products & services offered
15.1.8 CHARLES RIVER LABORATORIES
15.1.8.1 Business overview
15.1.8.2 Products & services offered
15.1.8.3 Recent developments
15.1.8.3.1 Deals
15.1.9 BIO-RAD LABORATORIES, INC.
15.1.9.1 Business overview
15.1.9.2 Products & services offered
15.1.9.3 Recent developments
15.1.9.3.1 Product launches
15.1.9.3.2 Deals
15.1.10 EUROFINS SCIENTIFIC
15.1.10.1 Business overview
15.1.10.2 Products & services offered
15.1.10.3 Recent developments
15.1.10.3.1 Deals
15.1.11 BIOMERIEUX
15.1.11.1 Business overview
15.1.11.2 Products & services offered
15.1.11.3 Recent developments
15.1.11.3.1 Product launches & approvals
15.1.11.3.2 Deals
15.1.12 ILLUMINA, INC.
15.1.12.1 Business overview
15.1.12.2 Products & services offered
15.1.12.3 Recent developments
15.1.12.3.1 Product launches & approvals
15.1.12.3.2 Deals
15.1.13 JSR CORPORATION
15.1.13.1 Business overview
15.1.13.2 Products & services offered
15.1.13.3 Recent developments
15.1.13.3.1 Deals
15.1.14 GUARDANT HEALTH
15.1.14.1 Business overview
15.1.14.2 Products & services offered
15.1.14.3 Recent developments
15.1.14.3.1 Product launches & approvals
15.1.14.3.2 Deals
15.1.15 LABCORP
15.1.15.1 Business overview
15.1.15.2 Products & services offered
15.1.15.3 Recent developments
15.1.15.3.1 Product launches
15.1.16 QUANTERIX
15.1.16.1 Business overview
15.1.16.2 Products & services offered
15.1.16.3 Recent developments
15.1.16.3.1 Product launches
15.1.16.3.2 Deals
15.1.17 MESO SCALE DIAGNOSTICS, LLC
15.1.17.1 Business overview
15.1.17.2 Products & services offered
15.2 OTHER PLAYERS
15.2.1 CELERION
15.2.2 STANDARD BIOTOOLS
15.2.3 SEBIA
15.2.4 BIOAGILYTIX LABS
15.2.5 STRESSMARQ BIOSCIENCES INC.
15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC
15.2.7 SIGNOSIS
15.2.8 SERIMMUNE
15.2.9 THERAINDX LIFESCIENCES PVT. LTD.
15.2.10 SYNEXA LIFE SCIENCES BV
15.2.11 DIATECH PHARMACOGENETICS
15.2.12 SINGULEX, INC.
15.2.13 R-BIOPHARM AG

16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS